Hum Mol Genet. 1995 Dec;4(12):2233-7. doi: 10.1093/hmg/4.12.2233.
The von Hippel-Lindau disease (VHL) gene is a putative tumor suppressor gene responsible for VHL, an autosomal dominantly inherited multitumor syndrome. It is also implicated in the development of sporadic tumors including clear cell renal carcinoma and central nervous system hemangioblastoma. To define the molecular basis of VHL patients in Japanese populations, we tested for germline mutations of the VHL gene in 45 unrelated Japanese VHL patients by single-strand conformation polymorphism (SSCP) analysis and Southern blot analysis. We detected 23 (51%) intragenic mutations and three (6.7%) deletions by SSCP analysis and Southern blot respectively. The intragenic mutations consisted of 14 missense mutations, seven microdeletions or insertions and two splice-site mutations. Interestingly, nine of 10 mutations in exon 1 are localized in a short region of 37 nucleotides. Five unique sites of mutation were included, which were not seen in previous studies. Unlike Western VHL patients, nonsense mutations were not found in Japanese VHL patients. If the presence of pheochromocytomas is regarded as phenotypic marker for VHl classification, the mutations found in 22 VHL patients without pheochromocytoma consisted of 11 missense mutations, six microdeletions or insertions, two splice-site alterations and three deletions. The mutations found in four VHL patients with pheochromocytomas consisted of one missense mutation at nucleotide 683 (codon 228), two missense mutations at nucleotide 712 (codon 238) and a novel 20 bp insertion at nucleotide 776 (codon 259). Although the mutations at codon 238 are the mutational hot spot found in Western VHL patients with pheochromocytomas, a 20 bp insertion of original VHL cDNA sequence, from nucleotide 777 to 796, is a unique mutation. Our results suggest that mutations in Japanese VHL patients contain some unique features compared with those in Western patients. VHL gene has a critical role for the etiology in VHL in Japanese populations as well as Western VHL.
冯·希佩尔-林道病(VHL)基因是一种推定的肿瘤抑制基因,与VHL这种常染色体显性遗传的多肿瘤综合征相关。它也与包括透明细胞肾癌和中枢神经系统血管母细胞瘤在内的散发性肿瘤的发生有关。为了明确日本人群中VHL患者的分子基础,我们通过单链构象多态性(SSCP)分析和Southern印迹分析,对45名无亲缘关系的日本VHL患者的VHL基因种系突变进行了检测。我们通过SSCP分析和Southern印迹分析分别检测到23个(51%)基因内突变和3个(6.7%)缺失。基因内突变包括14个错义突变、7个微缺失或插入以及2个剪接位点突变。有趣的是,外显子1中的10个突变中有9个位于37个核苷酸的短区域内。其中包含5个独特的突变位点,这些位点在先前的研究中未被发现。与西方VHL患者不同,日本VHL患者中未发现无义突变。如果将嗜铬细胞瘤的存在视为VHL分类的表型标志物,那么在22名无嗜铬细胞瘤的VHL患者中发现的突变包括11个错义突变、6个微缺失或插入、2个剪接位点改变和3个缺失。在4名患有嗜铬细胞瘤的VHL患者中发现的突变包括核苷酸683(密码子228)处的1个错义突变、核苷酸712(密码子238)处的2个错义突变以及核苷酸776(密码子259)处的一个新的20 bp插入。尽管密码子238处的突变是在患有嗜铬细胞瘤的西方VHL患者中发现的突变热点,但从核苷酸777到796的原始VHL cDNA序列的20 bp插入是一个独特的突变。我们的结果表明,与西方患者相比,日本VHL患者的突变具有一些独特特征。VHL基因在日本人群以及西方VHL的病因学中都起着关键作用。